Nanomaterials in cancer immunotherapy: targeting cancer-associated fibroblasts

Cancer Nanotechnology, Journal Year: 2025, Volume and Issue: 16(1)

Published: Jan. 17, 2025

Emphasizing the significance of cancer-associated fibroblasts (CAFs), non-malignant yet pivotal players within tumor microenvironment (TME), this review illuminates role inflammatory subtype (iCAF) as catalysts in cancer proliferation, metastasis, and therapeutic resistance. Given their paramount importance, targeting CAFs emerges a robust strategy evolving landscape immunotherapy. Nanomaterials, distinguished by unique features malleability, hold considerable promise biomedicine, especially precision-oriented domain therapy. Their aptitude for modulating immune responses, amplifying drug efficacy through precise delivery, discerningly focusing on cells TME situates nanomaterials formidable tools to transcend boundaries set conventional treatments. This scrutinizes convoluted interplay among CAFs, cells, TME. It further showcases widely utilized management. We underscore potential nanoscale delivery systems directed at underscoring transformative power revolutionizing therapies, enhancing precision, culminating improved patient outcomes.

Language: Английский

Preparation and Therapeutic Evaluation of Engineered Semaglutide and Statin–Lipid Conjugate-Based Nanoparticle

Pharmaceutics, Journal Year: 2025, Volume and Issue: 17(4), P. 480 - 480

Published: April 7, 2025

Background: Fatty liver disease and obesity are among the most prevalent health conditions in modern society have recently garnered significant attention. Semaglutide, a well-known anti-obesity drug, has been widely used for diabetes treatment; however, nanotherapeutics utilizing semaglutide not yet developed. Methods: A novel statin–lipid conjugate was synthesized using rosuvastatin ursodeoxycholic acid, liver-protective agent. This then formulated with through hydrophobic interactions to create new nanoparticle system. The physicochemical properties of nanoparticles were analyzed, their therapeutic efficacy evaluated high-fat diet (HFD)-induced animal model. Results: successfully synthesized, forming an aqueous solution. These exhibited distinct compared conventional formulations. In experiments, treatment group demonstrated 30.24% reduction body weight 46.80% improvement function markers control group. Conclusions: study introduces semaglutide-based (SRLC NP) system that overcomes key limitations therapy by providing enhanced bioavailability, extended circulation time, improved cellular uptake. findings highlight potential SRLC NPs as clinically translatable nanotherapeutic approach more effective, sustained, patient-friendly fatty treatment.

Language: Английский

Self-assembled co-delivery system of gold nanoparticles and paclitaxel based on in-situ dynamic covalent chemistry for synergistic chemo-photothermal therapy

Rare Metals, Journal Year: 2024, Volume and Issue: unknown

Published: Dec. 6, 2024

Language: Английский